Commentary | Published:

Precompetitive consortia in biomedicine—how are we doing?

Nature Biotechnology volume 31, pages 979985 (2013) | Download Citation

Too few precompetitive consortia are being formed to mitigate lost opportunities and deliver on other potential mutual gains for public and private stakeholders in drug development.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    FDA. The beginnings: laboratory and animal studies. Information for Consumers (Drugs) (2011).

  2. 2.

    Necessity driving leery pharma “open.” FiercebiotechIT (2013).

  3. 3.

    Drug makers join efforts in research. New York Times (20 September 2012).

  4. 4.

    & Valuing the commons: a fundamental challenge across complex systems. (NSF, Washington, DC, 2010).

  5. 5.

    & Drug Discov. Today 16, 643–645 (2011).

  6. 6.

    , , & Nat. Rev. Drug Discov. 10, 241–242 (2011).

  7. 7.

    , & J. Health Econ. 22, 151–185 (2003).

  8. 8.

    Toronto International Data Release Workshop Authors. Nature 461, 168–170 (2009).

  9. 9.

    & Nat. Rev. Drug Discov. 9, 87–88 (2010).

  10. 10.

    Clin. Pharmacol. Ther. 87, 534–536 (2010).

  11. 11.

    , , , & Aviation and the environment: a national vision statement, goals and recommended actions. (FAA/NASA, Washington, DC, 2004).

  12. 12.

    & Open source for neglected diseases: magic bullet or mirage? (Results for Development Institute, Washington, DC, 2011).

  13. 13.

    , , , & Stakeholder alignment in the Biomarkers Consortium. (NSF-VOSS EAGER 0956472, Washington, DC, 2012).

  14. 14.

    , & Nat. Chem. 3, 745–748 (2011).

  15. 15.

    , & Building the internal organization to support lateral alignment: a case study of the Office of Environment and Energy, Federal Aviation Administration (MIT, Cambridge, Massachusetts, 2005).

  16. 16.

    & A Behavioral Theory of Labor Negotiations. (McGraw Hill, New York, 1965).

  17. 17.

    , & The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151–185 (2003).

  18. 18.

    et al. Clin. Pharmacol. Ther. 86, 619–625 (2009).

Download references

Acknowledgements

We appreciate support for this research provided under NSF-VOSS EAGER 0956472, “Stakeholder Alignment in Socio-Technical Systems.”

Author information

Affiliations

  1. Barbara Mittleman was at the US National Institutes of Health, Bethesda, Maryland, USA and is presently at Nodality, South San Francisco, California, USA.

    • Barbara Mittleman
  2. Garry Neil is at Johnson & Johnson, New Brunswick, New Jersey, USA.

    • Garry Neil
  3. Joel Cutcher-Gershenfeld is at the University of Illinois at Urbana-Champaign, Illinois, USA.

    • Joel Cutcher-Gershenfeld

Authors

  1. Search for Barbara Mittleman in:

  2. Search for Garry Neil in:

  3. Search for Joel Cutcher-Gershenfeld in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Barbara Mittleman.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.2731

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing